The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has reached the market that could further alter the HF landscape. The FDA has ...
A structured, tiered catalogue of standards for heart failure outcome measures has been developed via a major international ...
When the heart struggles to pump efficiently, a cascade of events unfolds. Fluid accumulates in the lungs and extremities. Breathing becomes labored. Simple activities like climbing stairs or carrying ...
Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results